AI brief of an SEC Form 8-K · Cingulate Inc. (CING)
Cingulate CEO outlines CTx-1301 NDA resubmission timing, now expected December 2026 to January 2027
Cingulate's chairman and CEO discussed the company's work on the FDA's June 1, 2026 Complete Response Letter for CTx-1301 in a November 10, 2026 interview and press release. The company expects to resubmit the NDA between December 2026 and January 2027 and currently targets a commercial launch in the third quarter of 2027, subject to FDA approval, though the company states there is no assurance of resubmission timing, acceptance, or approval.
Key points
- FDA issued a Complete Response Letter on June 1, 2026, requesting additional chemistry, manufacturing and controls (CMC) information and raising no concerns about clinical safety or efficacy.
- Cingulate and its contract manufacturer have substantially completed the required CMC manufacturing work and expect to submit the NDA resubmission between December 2026 and January 2027.
- A Class 1 resubmission carries a two-month review goal and a Class 2 resubmission a six-month goal; the company currently expects a commercial launch as early as the third quarter of 2027, subject to approval.
The filing
CompanyCingulate Inc. (CING)
Form8-K, current report
Filed with the SECNov 10, 2026, 8:10 AM ET
Accession number0001493152-26-050870
Written by AI on Nov 10, 2026, 8:25 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.